Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Background Type 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well as potent T cell priming ability. Tissue-resident cDC1s (CD103 + cDC1s in mice, CD141 + cDC1s in humans) are linked with improved tumor control, yet the efficacy of immunotherapy using this population is understudied. Methods We generated murine CD103 + cDC1s in vitro and examined their expression of cDC1-related factors, antigen cross-presentation activity, and accumulation in tumor-draining lymph nodes (TdLNs). The antitumor efficacy of the in vitro-generated CD103 + cDC1s was studied in murine melanoma and osteosarcoma models. We evaluated tumor responses on vaccination with CD103 + cDC1s, compared these to vaccination with monocyte-derived DCs (MoDCs), tested CD103 + cDC1 vaccination with checkpoint blockade, and examined the antimetastatic activity of CD103 + cDC1s. Results In vitro-generated CD103 + cDC1s produced cDC1-associated factors such as interleukin-12p70 and CXCL10, and demonstrated antigen cross-presentation activity on stimulation with the toll-like receptor 3 agonist polyinosinic:polycytidylic acid (poly I:C). In vitro-generated CD103 + cDC1s also migrated to TdLNs following poly I:C treatment and intratumoral delivery. Vaccination with poly I:C-activated and tumor antigen-loaded CD103 + cDC1s enhanced tumor infiltration of tumor antigen-specific and interferon-γ + CD8 + T cells, and suppressed melanoma and osteosarcoma growth. CD103 + cDC1s showed superior antitumor efficacy compared with MoDC vaccination, and led to complete regression of 100% of osteosarcoma tumors in combination with CTLA-4 antibody-mediated checkpoint blockade. In vitro-generated CD103 + cDC1s effectively protected mice from pulmonary melanoma and osteosarcoma metastases. Conclusions Our data indicate an in vitro-generated CD103 + cDC1 vaccine elicits systemic and long-lasting tumor-specific T cell-mediated cytotoxicity, which restrains primary and metastatic tumor growth. The CD103 + cDC1 vaccine was superior to MoDCs and enhanced response to immune checkpoint blockade. These results indicate the potential for new immunotherapies based on use of cDC1s alone or in combination with checkpoint blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This treatment activates and loads tumor antigens onto CD103+ myeloid/conventional DC1s, enhancing the immune system’s capacity to target cancer cells [151].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A variety of vaccines have shown encouraging results, including the CD1c+ DC vaccine, which harnesses the power of antigen-presenting DCs, and the innovative approach of vaccinating with polyinosinic: polycytidylic acid (poly I: C).”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [151]
Experimental — accuracy not yet measuredIn the citing paper
“Recent preclinical studies have shown that vaccination with CD103+ cDC1s in combination with CTLA-4 blockade were highly effective in inducing tumor regression in murine models of osteosarcoma and melanoma (Zhou et al., 2020).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Zhou et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Tumor metastasis: mechanistic insights and clinical challenges
Steeg, P. S. (2006) · Nature Medicine · doi:10.1038/nm1469 · Cited by 2,134
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Engineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & De Palma, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 505
Transcriptional Control of Dendritic Cell Development
Murphy, T. L., Grajales-Reyes, G. E., Wu, X., Tussiwand, R., Briseño, C. G., Iwata, A., Kretzer, N. M., Durai, V., & Murphy, K. M. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120204 · Cited by 489
Disis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 489
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Self-citationDendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 377
Tel, J., Aarntzen, E. H. J. G., Baba, T., Schreibelt, G., Schulte, B. M., Benitez-Ribas, D., Boerman, O. C., Croockewit, S., Oyen, W. J. G., van Rossum, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2583 · Cited by 353
Development of Dendritic-Cell Lineages
Wu, L., & Liu, Y.-J. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.006 · Cited by 343
Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.006 · Cited by 340
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 305
Schreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H. J. G., Duiveman-de Boer, T., van de Rakt, M. W. M. M., Scharenborg, N. M., de Boer, A. J., Pots, J. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2205 · Cited by 241
Mayer, C. T., Ghorbani, P., Nandan, A., Dudek, M., Arnold-Schrauf, C., Hesse, C., Berod, L., Stüve, P., Puttur, F., Merad, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-545772 · Cited by 219
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 165
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
Anguille, S., Smits, E., Bryant, C. E., Acker, H. H. V., Goossens, H., Lion, E., Fromm, P. D., Hart, D. N. J., Tendeloo, V. F. V., & Berneman, Z. N. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009456 · Cited by 161
T Cell Fate at the Single-Cell Level
Buchholz, V. R., Schumacher, T. N. M., & Busch, D. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112014 · Cited by 156
Mechanisms regulating dendritic cell specification and development
Watowich, S. S., & Liu, Y. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00949.x · Cited by 148
Self-citationWimmers, F., Schreibelt, G., Sköld, A. E., Figdor, C. G., & De Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00165 · Cited by 148
Wculek, S. K., Amores-Iniesta, J., Conde-Garrosa, R., Khouili, S. C., Melero, I., & Sancho, D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0565-5 · Cited by 143
Towards superior dendritic-cell vaccines for cancer therapy
Saxena, M., Balan, S., Roudko, V., & Bhardwaj, N. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0250-x · Cited by 131
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 122
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma
Kleinerman, E. S., Gano, J. B., Johnston, D. A., Benjamin, R. S., & Jaffe, N. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199504000-00001 · Cited by 116
Self-citationMiwa, S., Nishida, H., Tanzawa, Y., Takeuchi, A., Hayashi, K., Yamamoto, N., Mizukoshi, E., Nakamoto, Y., Kaneko, S., & Tsuchiya, H. (2017) · Cancer · doi:10.1002/cncr.30606 · Cited by 95
Emerging trends in immunotherapy for pediatric sarcomas
Dyson, K. A., Stover, B. D., Grippin, A., Mendez-Gomez, H. R., Lagmay, J., Mitchell, D. A., & Sayour, E. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0756-z · Cited by 88
Himoudi, N., Wallace, R., Parsley, K. L., Gilmour, K., Barrie, A.-U., Howe, K., Dong, R., Sebire, N. J., Michalski, A., Thrasher, A. J., et al. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0795-1 · Cited by 74
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
Bol, K. F., Aarntzen, E. H. J. G., Hout, F. E. M. I. '., Schreibelt, G., Creemers, J. H. A., Lesterhuis, W. J., Gerritsen, W. R., Grunhagen, D. J., Verhoef, C., Punt, C. J. A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1057673 · Cited by 72
Gordon, N., Koshkina, N. V., Jia, S.-F., Khanna, C., Mendoza, A., Worth, L. L., & Kleinerman, E. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0313 · Cited by 68
Self-citationChrisikos, T. T., Zhou, Y., Slone, N., Babcock, R. L., Watowich, S. S., & Li, H. S. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.01.014 · Cited by 65
Self-citationGeneration of mouse and human dendritic cells in vitro
Guo, X., Zhou, Y., Wu, T., Zhu, X., Lai, W., & Wu, L. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.02.011 · Cited by 42
Self-citationMaximum benefit of chemotherapy for osteosarcoma achieved—what are the next steps?
Kleinerman, E. S. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30270-4 · Cited by 36
Self-citationLiu, C., Zhou, Y., Li, M., Wang, Y., Liu, Y., Yang, S., Feng, Y., Wang, Y., Wang, Y., Ren, F., et al. (2019) · Theranostics · doi:10.7150/thno.32451 · Cited by 30
Self-citationImmune‐related Adverse Events in Cancer Patients
Pallin, D. J., Baugh, C. W., Postow, M. A., Caterino, J. M., Erickson, T. B., & Lyman, G. H. (2018) · Academic Emergency Medicine · doi:10.1111/acem.13443 · Cited by 29
Gianan, M. A., & Kleinerman, E. S. (1998) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1998.13.363 · Cited by 23
Self-citation
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 383
“Furthermore, endogenous mouse and human cDCs are more efficient antigen presenters and inducers of T cell responses than DCs generated ex vivo with GM-CSF 214–217 .”
InfluentialAdvances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 232
Metadata
- Authors
- Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Watowich, Stephanie S
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-04
- Volume
- 8
- Issue
- 1
- Pages
- e000474
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7254126
- OpenAlex
- W3015270738
- Cited by
- 112
- References
- 48
- Citations by year
- 2026: 9 · 2025: 26 · 2024: 14 · 2023: 22 · 2022: 22 · 2021: 11 · 2020: 7
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Allergy and Infectious Diseases (3R01AI109294-04S1, R01AI109294)
- Cancer Prevention and Research Institute of Texas (RP170067)
- National Cancer Institute (P30CA016672)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dendritic cell vaccine, cancer immunotherapy, cross-presentation, tumor-draining lymph nodes, melanoma, osteosarcoma, metastasis, CTLA-4 blockade, immune checkpoint blockade, monocyte-derived dendritic cells, IL-12, CXCL10, tumor-specific T cells, poly(I:C)
- MeSH terms
- Animals, Antigens, Neoplasm, Bone Neoplasms, Dendritic Cells, Immunotherapy, Lung Neoplasms, Melanoma, Experimental, Mice, Inbred C57BL, Sarcoma, Experimental, Osteosarcoma, Tumor Cells, Cultured, Vaccines, Antigens, CD, Antigen Presentation, Integrin alpha Chains, Cross-Priming, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.